Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Erythromycin Ethylsuccinate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 10/20 | 1.00 |
| ▸ | SLCO1B3 | Q9NPD5 | 3/20 | 1.00 |
| ▸ | SLCO1B1 | Q9Y6L6 | 3/20 | 1.00 |
| ▸ | USP2 | O75604 | 3/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 0.88 |
| ▸ | HTR1A | P08908 | 1/20 | 0.88 |
| ▸ | DRD1 | P21728 | 1/20 | 0.88 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.88 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.88 |
| ▸ | DRD3 | P35462 | 1/20 | 0.88 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.88 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.79 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.79 |
| ▸ | TSHR | P16473 | 2/20 | 0.79 |
| ▸ | LMNA | P02545 | 2/20 | 0.79 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.79 |
| ▸ | MLNR | O43193 | 1/20 | 0.79 |
| ▸ | ALB | P02768 | 1/20 | 0.79 |
| ▸ | CNR1 | P21554 | 1/20 | 0.79 |
| ▸ | HTR2A | P28223 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Erythromycin Ethylsuccinate SCHEMBL7866739 | 1.00 | CYP3A4 (1.00) | CYP3A4SLCO1B3SLCO1B1USP2PGR | |
| Erythromycin Ethylsuccinate SCHEMBL5082211 | 1.00 | CYP3A4 (1.00) | CYP3A4SLCO1B3SLCO1B1USP2PGR | |
| Erythromycin Ethylsuccinate SCHEMBL18259 | 1.00 | CYP3A4 (1.00) | CYP3A4SLCO1B3SLCO1B1USP2PGR | |
| Erythromycin Ethylsuccinate SCHEMBL9807840 | 0.99 | CYP3A4 (0.99) | CYP3A4SLCO1B3SLCO1B1USP2PGR | |
| Erythromycin Ethylsuccinate SCHEMBL15665988 | 0.99 | CYP3A4 (0.99) | CYP3A4SLCO1B3SLCO1B1USP2PGR | |
| Erythromycin Ethylsuccinate SCHEMBL10673952 | 0.99 | CYP3A4 (0.99) | CYP3A4SLCO1B3SLCO1B1USP2PGR | |
| Erythromycin Ethylsuccinate SCHEMBL9118779 | 0.99 | CYP3A4 (0.99) | CYP3A4SLCO1B3SLCO1B1USP2PGR | |
| Erythromycin Ethylsuccinate SCHEMBL10382844 | 0.99 | CYP3A4 (0.99) | CYP3A4SLCO1B3SLCO1B1USP2PGR | |
| Erythromycin Ethylsuccinate SCHEMBL7750959 | 0.99 | CYP3A4 (0.98) | CYP3A4SLCO1B3SLCO1B1USP2PGR | |
| Erythromycin Ethylsuccinate SCHEMBL7755531 | 0.98 | CYP3A4 (0.97) | CYP3A4SLCO1B3SLCO1B1USP2PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 171 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9227999-B2 | Antimicrobial cationic peptides and formulations thereof | CARRUS CAPITAL CORPORATION (CA) | 2016-01-05 | — | — | US | claimed |
| EP-3866826-B1 | ANTIMICROBIAL PEPTIDES AND METHODS OF USING THE SAME | RIPTIDE BIOSCIENCE INC (US) | 2025-12-10 | — | — | EP | disclosed |
| US-11266712-B2 | Antimicrobial peptides and methods of using the same | Riptide Bioscience, Inc. (US) | 2022-03-08 | — | — | US | disclosed |
| CN-108794552-B | Erythromycin ethylsuccinate spherical crystal and preparation method thereof | 天津大学 | 2021-12-07 | — | — | CN | disclosed |
| CN-113226349-A | Antimicrobial peptides and methods of use thereof | 激流生物科学有限公司 | 2021-08-06 | — | — | CN | disclosed |
| US-20210144998-A1 | COMPOSITIONS AND METHODS FOR TREATING HUANGLONGBING DISEASE IN CITRUS | NEW LIFE CROP SCIENCES LLC | 2021-05-20 | — | — | US | disclosed |
| US-20210087565-A1 | ANTISENSE ANTIBIOTICS AND BACTERIAL SECRETION BASED DELIVERY SYSTEM TO ELIMINATE DRUG-RESISTANT BACTERIA | NATIONAL SCIENCE FOUNDATION | 2021-03-25 | — | — | US | disclosed |
| US-10913790-B2 | Compositions of, and methods for, alpha-1 anti trypsin Fc fusion molecules | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2021-02-09 | — | — | US | disclosed |
| US-20200385715-A1 | COMPOSITIONS AND METHODS FOR ALTERING BACTERIA FITNESS | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2020-12-10 | — | — | US | disclosed |
| US-10842811-B2 | Inulin for preventing antibiotic resistant infection and pathogen colonization | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2020-11-24 | — | — | US | disclosed |
| EP-0925308-B1 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING ANALOGUES OF INDOLICIDIN | MICROLOGIX BIOTECH INC (CA) | 2002-06-05 | — | — | EP | disclosed |
| US-20020035061-A1 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING CATIONIC PEPTIDES ALONE OR IN COMBINATION WITH ANTIBIOTICS | BIOWEST THERAPEUTICS INC. (CA) | 2002-03-21 | — | — | US | disclosed |
| EP-1174439-A2 | Compositions and methods for treating infections using analogues of indolicidin | Micrologix Biotech, Inc. (CA) | 2002-01-23 | — | — | EP | disclosed |
| US-6180604-B1 | Compositions and methods for treating infections using analogues of indolicidin | MICROLOGIX BIOTECH INC. (CA) | 2001-01-30 | — | — | US | disclosed |
| EP-0966481-A2 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING CATIONIC PEPTIDES ALONE OR IN COMBINATION WITH ANTIBIOTICS | Micrologix Biotech, Inc. (CA) | 1999-12-29 | — | — | EP | disclosed |
| WO-1999065506-A2 | CANCER THERAPY WITH INDOLICIDIN OR CATIONIC PEPTIDES AND THEIR POLYMER CONJUGATES | MICROLOGIX BIOTECH INC. (CA) | 1999-12-23 | — | — | WO | disclosed |
| EP-0925308-A2 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING ANALOGUES OF INDOLICIDIN | Micrologix Biotech, Inc. (CA) | 1999-06-30 | — | — | EP | disclosed |
| WO-1998040401-A2 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING CATIONIC PEPTIDES ALONE OR IN COMBINATION WITH ANTIBIOTICS | MICROLOGIX BIOTECH INC. (CA) | 1998-09-17 | — | — | WO | disclosed |
| WO-1998007745-A9 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING ANALOGUES OF INDOLICIDIN | — | 1998-04-23 | — | — | WO | disclosed |
| WO-1998007745-A2 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING ANALOGUES OF INDOLICIDIN | MICROLOGIX BIOTECH, INC. (CA) | 1998-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035061-A1 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING CATIONIC PEPTIDES ALONE OR IN COMBINATION WITH ANTIBIOTICS | VIP, PEPD, PTMS | CYP3A4 3005/4885SLCO1B3 2921/4885SLCO1B1 3083/4885 |
| US-20210144998-A1 | COMPOSITIONS AND METHODS FOR TREATING HUANGLONGBING DISEASE IN CITRUS | PNPO, G6PD, AGXT | CYP3A4 1568/4885SLCO1B3 191/4885SLCO1B1 301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.